Fortis Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Fortis Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,011	Closed	-$641K	–	274
2025 Q1	$641K	Sell	1,011 -660	-39%	-$454K	0.13%	134
2024 Q4	$1.98M	Buy	1,671 +132	+9%	+$111K	0.68%	22
2024 Q3	$1.62M	Buy	1,539 +32	+2%	+$35.6K	0.54%	32
2024 Q2	$1.58M	Buy	1,507 +457	+44%	+$443K	0.57%	27
2024 Q1	$1.01M	Buy	1,050 +721	+219%	+$686K	0.43%	41
2023 Q4	$289K	Sell	329 -16	-5%	-$13.2K	0.15%	91
2023 Q3	$284K	Sell	345 -28	-8%	-$22K	0.18%	79
2023 Q2	$268K	Sell	373 -104	-22%	-$80.2K	0.16%	88
2023 Q1	$392K	Sell	477 -141	-23%	-$106K	0.21%	66
2022 Q4	$446K	Buy	+618	New	+$456K	0.27%	56

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fortis Capital Advisors's REGN Position: Q2 2025 in Review

Fortis Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 1,011 shares — an estimated $641K sold.

Fortis Capital Advisors first reported a position in REGN in Q4 2022 and held it in 10 quarters. The position peaked at $1.98M in Q4 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Fortis Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Fortis Capital Advisors sold 1,011 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $641K.
Fortis Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 10 quarters.
Fortis Capital Advisors's Regeneron Pharmaceuticals position peaked at $1.98M in Q4 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Fortis Capital Advisors's 13F filing for Q2 2025, filed 21 Jul 2025.